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802-5 Datermlnsnts and Outcomes of Congestive Heart 
Failure Complicat ing Acute Coronary Syndromes: 
Observations From the Global Registry of Acute 
Coronary Events 
Philiooe Gabriel Stea, Omar Dabbeus, Alain Cohen-Solal, Marie-Claude Aumont, 
Christopher P. Cannon, Josd L6paz-Sendbn, Andrzej Budaj, Werner Klein, for the 
GRACE investigators, Hospital Bichat, Paris, France. 
Background Coronary artery disease is the leading attributable cause of congestive 
heart failure (CHF) in industrialized countries. Yet little is known about the determinants 
and outcomes of CHF complicating acute coronary syndromes (ACS), at least outside of 
the selected patient populations enrolled in clinical trials. 
Methods GRACE is a prospective registry enrolling ACS patients from 94 hospitals in 14 
countdes. Patients admitted to GRACE hospitals were stratified according to the pres- 
ence or absence of CHF (Killip class 2 or 3) at admission. Patients with a prior history of 
CHF or in cardiogenic shock were excluded. 
Reaulte Data from 10,655 ACS patients were analyzed. Selected variables are shown in 
the table. CHF was a frequent complication in all forms of ACS, including 9% of unstable 
angina patients. Multivariate analysis showed that the main predictors of CHF were (in 
order): age (OR 1.06/year), systolic blood pressure (OR:0.99/mm Hg), cardiac arrest at 
admission (OR 5.17), STEMI (OR 2.6), heart rate (OR 1.01/beat), initial creatinine 
(OR:1.28), Q-waves (OR 1.54), and diabetes (OR 1.54). CHF was associated with less 
frequent use of percutaneous procedures, a reduced use of ~ -blockers, a more than 
threefold increase in the in-hospital death rate and a prolonged hospital stay across all 
ACS subsets. 
Concluelone: CHF is a common and ominous complication of all forms of ACS. Rela- 
tively infrequent invasive management of patients with CHF represents opportunities for 
improved care. 
STEMI (N=3630) NSTEMI (N=2890) UA (N=4135) 
CHF+ CHF- P CHF+ CHF- P CHF+ CHF- P 
N (%) 15 85 16 84 9 91 
Age(yrs) 69.7 62.2 <.0001 73.1 64.6 <.0001 70.1 63.9 <.0001 
Male(%) 61.1 75.3 <.0001 58.8 70.7 <.0001 60.4 64.8 .0989 
Diabetes(%) 26.7 18.6 <.0001 33.6 21.6 <.0001 29.6 22.4 .0024 
Cardlaccath(%) 54.6 56.3 .4757 46.8 59.3 <.0001 32.9 45.1 <.0001 
PCI (%) 36.4 41.6 .1503 21.0 32.2 <.0001 16.2 19.6 .1260 
Hospital death (%) 15.3 4.1 <.0001 9.9 2.8 <.0001 7.0 1.6 <.0001 
Length of stay (days) 11.09 9.01 <.0001 10.27 7.96 <.0001 7.31 7.16 .2882 - 
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808-1 Clinical Predictore of In-Hospital Death in Patients With 
Cardlogenic Shock Selected to Undergo Early 
Revaecularizstion 
Simon R. Dixon, Hasean Alkafri, Aziz Chami, Mark Pica, Judith A. Boura, William W. 
O'Neill, Wi//iam Beaumont Hospital, Royal Oak, Michigan. 
Background. Patients with cardiogenic shock (CS) secondary to acute myocardial inf- 
arction (AMI) have a dismal prognosis even with an eady revascularization strategy. Clin- 
icsl predictors of survival after percutaneous revasculadzation for CS have not been well 
defined. 
Methods, From 1993-1999, 264 AMI patients with CS were admitted to William Beau- 
mont Hospital Of these 136 (52%) were selected to undergo percutaneous revascular- 
ization within 24-hours of shock-onset. CS was defined according to criteria established 
by the SHOCK investigators. Baseline clinical variables were examined to identify predic- 
tors of in-hospital death. 
Results. The mean in-hospital mortality from 1993-1999 was 52%. No significant change 
in the mortality rate was observed during this period (p=0.67). Patients who died were 
more likely to be older (67 + 11 vs. 63 + 10 yre, p=0.05), have a higher heart rate (HR 92 
+ 30 vs. 74 :t: 32, p=0.048), higher serum glucose (277 vs. 228mg/dL, p=0.045), higher 
serum craatinine (1.8 + 1.4 vs. 1.15 ± 0.3 mg/dL, p=0.0012), and a history of congestive 
heart failure (CHF 46% vs. 22%, p=0.009) or peripheral vascular disease (PVD 25% vs. 
9%, p=0.024). Infarct location and blood pressure did not correlate with in-hospital death. 
Using multiple stepwise logistic regression analysis, independent clinical predictors of in- 
hospital death were: creatinine clearance < 75ml/min (OR 7.9, CI 1.03-62.4, p=0.04), HR 
> 100/rain (OR 13.1, CI 1.14-151), and a history of PVD (OR 38.6, CI 2.1-724, p=0.01) or 
CHF (OR 17.6, CI 2.23-134, p=0.005). 
Conclusion. Baseline clinical variables provide important prognostic information in 
patients with CS undergoing eady percutaneous revascutarization. These data permit 
eady risk stratification and may improve selection of patients with CS who will benefit 
from mechanical repertusion. 
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808-2 Do Women With Refractory Angina Respond as Well as 
Men to Treatment With Enhanced External 
CounterpulsaUon? 
William E. Lawson, Elizabeth Kennard, Georgiann Linnemeier, Richard Holubkov, 
Mandeep Mehre, IEPR Investigators, SUNY, Stony Brook, New York, U of Pittsburgh 
School of Public Health, Pittsburgh, Pennsylvania. 
Background:Women (F) benefit less and have greater morbidity and mortality than men 
(M) with revasculadzation for severe coronary disease. Enhanced exlemal counterpulse- 
tion (EECP) successfully treats angina refractory to medical therapy in patients (pts)with 
limited revascularization options. Whether F tolerate and benefit equally from EECP in 
this high risk group of pts was studied. 
Methods: 3,126 consecutive pts (Ms 2,340; F = 786)in the Intemationat EECP Patient 
Registry were analyzed by intention to treat using unpaired t test and multiple logistic 
regression for compadsion of demographics, adverse events and dropout, angina and 
quality of life outcomes; significance at p<0.05. 
Results: Groups were similar in: age (66.4 ± 10.4 years), duration of coronary disease 
(10 years), prior angioplasty (63%), hypedipidemia, non-cardiac vascular disease. The 
groups M vs F differed significantly in: prior bypass (69.7 vs 61.2%), prior infarct (68.5 vs 
60.2%), heart failure (29.3 vs 33.2%), diabetes (38.6 vs 53.0%), hypertension (67.8 vs 
77.1%), ejection fraction (45.1 vs 49.6%), multivessel coronary disease(80.2 vs 71.2%), 
candidate for revasculadzation (20.3% vs 28.9%). Events during EECP were comparable 
in both groups. However, F gender was a predictor (odds ratio 1.62; confidence interval 
[CI] 1.32-1.99) of failure to complete the usual prescribed 35 hours of EECP, along with 
current smoking (odds ratio 1.84; CI 1.33-2.53) and heart failure (odds ratio 1.51: CI 
1.24-1.84). Despite this, F gender was not a predictor of failure to reduce angina (odds 
ratio 0.93: CI 0.75-1.16). At baseline 80.2% of M and 84.8% of F were in Canadian Car- 
diovasuclar System Angina Class Ill/IV. Post EECP 73.3% of M and 70.9% of F improved 
> 1 angina class and only 24% of M and 31.8% of F remained in angina class Ill/IV; 
17.8% of M and 13.8% of F were angina free. Satisfaction, health and quality of life mea- 
sures improved comparably and significantly with EECP treatment in both groups. 
Conclusions: Despite increased diabetes and heart failure and lower EECP augmenta- 
tion, women improved equally and significantly in CCS anginal class and in quality of life 
measures. Women demonstrate benefits equal to men with EECP treatment. 
9:45 a.m. 
808-3 Temporal Trends in Percutaneous Treatment for  
Cardiogenic Shock Due to Acute Myocardial Infarction: 
Have Stents and Glycoprotein Receptor Inhlbitors 
Improved Outcome? 
Hassan Alkafd. Simon R. Dixon, Aziz Chami, Mark Pica, Judith A. Boura, William W. 
O'Neill, William Beaumont Hospital, Royal Oak, Michigan. 
Background. Cardiogenic shock (CS) is the leading cause of death in patients present- 
ing with acute myocardial infarction (AMI). Few data exist regarding the impact of more 
recent interventional strategies and adjunctive therapies on clinical outcome in this popu- 
lation. 
Methods. From 1993 to 1999, 264 patients with CS secondary to AMI were admitted to 
our institution. Of these 136 (52%) were selected to undergo percutanecus revascular- 
tzation within 24-hours of shock-onset. Trends in the utilization of stents and glycoprotein 
receptor inhibitors (llbllla) were examined in relation to the incidence of in-hospital death. 
Results. The use of adjunctive Ilbtila inhibitors increased significantly during this period, 
particulady from 1996 (p<0.001 for trend). Stenting was performed more frequently from 
1995 (p for trend = 0.0012). The overall in-hospital mortality rate was 52% (n=70/136). 
No significant change in the mortality rate was observed from 1gg3-1999 (p=0.88). 
Conclusion. Despite increased utilization of Ilblita inhibitors and stents in the treatment 
of patients with CS secondary to AMI, this has not been associated with a significant 
improvement in hospital survival. 
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808-4 Abnormal Diurnal Pattern of Blood Pressure In Patients 
With Left Ventricular Assist Devices 
Umesh N. Khot. Bhupinder Singh, Tiffany Buds, Nicholas G. Smedira, Patrick M. 
McCarthy, Mike Yeager, James B. Young, Randall C. Starling, The Cleveland Clinic 
Foundation, Cleveland, Ohio. 
BACKGROUND= I n patients with left ventricular assist devices (LVAD), hypertension is a 
common clinical problem often requiring aggressive management. Furthermore, recent 
reports have suggested that hypertension may be a risk factor for the development of 
early device failure. Little is known regarding the pathophysiology of blood pressure (BP) 
